Critical Path Institute's Predictive Safety Testing Consortium (PSTC) Announces First-Ever Biomarker Qualification Decision by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) TUCSON, ...
TUCSON, Ariz., May 8, 2025 /PRNewswire/ -- The year 2025 marks a historic milestone for Critical Path Institute ® (C-Path), as the organization celebrates 20 years of transforming the landscape of ...
TUCSON, Ariz., Feb. 4, 2014 /PRNewswire-USNewswire/ -- The Critical Path Institute, an independent, non-profit that catalyzes innovative ideas that accelerate the speed of drug and medical product ...
TUCSON and FLAGSTAFF, Ariz. -- May 1, 2017 -- The Critical Path to TB Drug Regimens (CPTR), an initiative of the Critical Path Institute (C-Path), has received a $1.1 million grant from the Bill & ...
Tucson, AZ -- January 22, 2018 -- Critical Path Institute (C-Path) announced today that the European Medicines Agency (EMA) has issued a Letter of Support for measurement of glutamate dehydrogenase ...
TUCSON, Ariz.--(BUSINESS WIRE)-- Critical Path Institute (C-Path) is proud to announce that the Regulatory Science Consortium, an arm of the Critical Path to TB Drug Regimens (CPTR), has added 10 new ...
Marc Cantillon, MD, presents the critical role of public/private partnerships in creating innovative tools to advance the development of new Alzheimer’s disease therapies Despite alarming statistics ...
TUCSON, Ariz.--(BUSINESS WIRE)--Critical Path Institute (C-Path) announced today that Dr. Carolyn Compton has joined the organization as its new president and chief executive officer. Dr. Compton ...
TUCSON, Ariz.--(BUSINESS WIRE)-- A special May 10, 2010 issue of Nature Biotechnology (NBT) includes ten scientific publications from Critical Path Institute’s (C-Path) Predictive Safety Testing ...
The Tucson-based Critical Path Institute has no laboratories, no drug chemists, no patent lawyers. Yet the nonprofit is arguably one of the most important emerging drug-research organizations in the ...
Critical Path Institute (C-Path) today announced the launch of the Critical Path to Therapeutics for the Ataxias (CPTA) Consortium, a public-private partnership focused on optimizing clinical trials ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results